AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for NYSE:ABBV*
53.48
+0.59 (1.12%)
After Hours: 53.48 0.00 (0.00%)
Feb 9, 5:02PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 52.06 - 53.94
52 week 45.45 - 71.60
Open 52.31
Vol / Avg. 0.00/10.36M
Mkt cap 87.05B
P/E 17.02
Div/yield 0.57/4.26
EPS 3.14
Shares 1.63B
Beta 1.58
Inst. own 73%
May 6, 2016
AbbVie Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Apr 21, 2016
Q1 2016 AbbVie Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jan 29, 2016
Q4 2015 AbbVie Inc Earnings Release
Jan 29, 2016
Q4 2015 AbbVie Inc Earnings Call - Webcast
Jan 13, 2016
AbbVie Inc at JPMorgan Healthcare Conference
Nov 19, 2015
AbbVie Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 23.70% 22.50%
Operating margin 33.02% 32.97%
EBITD margin - 33.63%
Return on average assets - -
Return on average equity - -
Employees 26,000 -
CDP Score - 83 C

Address

1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson's disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and women's health. The Company's product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
William J. Chase Executive Vice President, Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President - Business Development, External Affairs, General Counsel
Age: 51
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 52
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 51
Bio & Compensation  - Reuters
Thomas A. Hurwich Vice President, Controller
Age: 54
Bio & Compensation  - Reuters
Roy S. Roberts Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters